Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 1

Pharmacogenetics of Response to GLP1R Agonists

University of Maryland, Baltimore · NCT05071898

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–89 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Phase 1
Target enrollment
600
US sites recruiting
1
Study start
April 11, 2022
Record last updated
July 27, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

Overweight/obese otherwise healthy volunteers will be recruited from the Old Order Amish population in Lancaster County, PA. Lancaster County, PA. Pharmacodynamic responses to GLP1R agonist will be assessed by conducting frequently sampled intravenous glucose tolerance tests (FSIGT) both before and after semaglutide for six weeks. The proposal proposes two specific aims:

  • Specific Aim #1. To identify genetic variants associated with effects of a GLP1R agonist to enhance glucose-stimulated first phase insulin secretion in the two FSIGTs (before and after administration of drug).
  • Specific Aim #2. To identify genetic variants associated with the effect of a GLP1R agonist to accelerate the rate of glucose disappearance as assessed in the two FSIGTs (before and after administration of drug).

Genotyping will be conducted using a high-density array with comprehensive coverage of DNA sequence variants. In addition, the analysis will leverage a global imputation panel generated from 1,025 Amish individuals.

Being studied: Semaglutide Pen Injector [Ozempic]

Conditions: Obesity; Diabetes Type 2

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • BMI greater than or equal to 27 kg/m2
  • Of Amish Descent

Exclusion Criteria

  • Woman of childbearing age who is sexually active
  • History of diabetes (HbA1c > 6.5% or random glucose >200 mg/dL)
  • Known allergy to semaglutide
  • Medical issues, which in the judgment of the research physician or PIs might increase the risk associated with participation in the study
  • eGFR \< 60 mL/min/1.73 sq. m.
  • Hematocrit \< 35%
  • TSH \< 0.4 o4 > 5.5
  • AST or ALT in excess of 2X the upper limit of normal
  • Unable to discontinue a drug, vitamin, or nutritional supplement, which in the judgment of the research physician or PIs might alter the response to semaglutide
  • Personal or family history of medullary carcinoma of the thyroid or multiple endocrine neoplasia, type 2

Recruiting US locations

  • Amish Research Clinic

    Lancaster, PA 17602

    Site contact: Susan Shaub, RN · (717)392-4948 · sshaub@som.umaryland.edu

Study contacts (from the official record)

  • Amber L Beitelshees, PharmD · (410)706-0118 · abeitels@som.umaryland.edu
  • Simeon I Taylor, MD, PhD · (410)706-6439 · staylor2@som.umaryland.edu
All weight loss studies in Pennsylvania →
Pharmacogenetics of Response to GLP1R Agonists (NCT05071898) | Bored Studies